Vaccine breakthrough cases | Total vaccinated | Person-weeks of vaccinated time at risk | Rate* | Unadjusted incidence rate ratio | Adjusted incidence rate ratio** | |||
---|---|---|---|---|---|---|---|---|
No | No | IRR | (95% CI) | aIRR | (95% CI) | |||
Sex | ||||||||
Male | 524 | 794,033 | 4,243,156 | 12.3 | Ref | Ref | ||
Female | 1,053 | 1,286,750 | 7,198,863 | 14.6 | 1.2 | (1.0–1.4) | 1.1 | (1.0–1.3) |
Age group | ||||||||
< 65 years | 965 | 1,001,871 | 6,387,727 | 15.1 | Ref | Ref | ||
65–84 years | 461 | 908,446 | 4,236,965 | 10.9 | 0.7 | (0.6–0.8) | 0.9 | (0.8–1.1) |
≥ 85 years | 156 | 179,215 | 869,710 | 17.9 | 1.2 | (0.9–1.5) | 1.6 | (1.3–2.0) |
Vaccine type | ||||||||
Moderna | 502 | 951,087 | 4,805,959 | 10.4 | Ref | Ref | ||
Pfizer | 1,073 | 1,136,729 | 6,678,125 | 16.1 | 1.5 | (1.3–1.8) | 1.4 | (1.2–1.6) |